Clinical trial NCT05374538: VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
Official title: A Phase 1a/1b Study of Aurora Kinase A Inhibitor VIC-1911 Monotherapy and in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Non-small Cell Lung Cancer
Keywords: KRAS G12C mutation
AURA kinase
VIC-1911
KRAS G12C
sotorasib
Lead sponsor: Vitrac Therapeutics, LLC
Sponsor class: INDUSTRY
Collaborators: name: Westat
First posted: 2022-05-16
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: Dose Escalation Phase followed by Expansion Phase. A total of 24 subjects are anticipated in Dose Escalation Phase, Cohort 1a. A total of 12 subjects are anticipated in Dose Escalation Phase, Cohort 1b. A total of 29 subjects are anticipated in Expansion Phase, Cohort 2a. A total of 29 subjects are anticipated in Expansion Phase, Cohort 2b. A total of 46 subjects are anticipated in Expansion Phase, Cohort 2c.
Primary purpose: TREATMENT

Brief summary: This is a Phase 1a/1b study of aurora kinase A inhibitor VIC-1911 administered as monotherapy and in combination with sotorasib for the treatment of locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer(NSCLC).

Detailed description: Selected subjects will include males and females age ≥18 years; histologically confirmed locally advanced or metastatic KRAS G12C-mutated NSCLC; received at least 1 prior line of cancer therapy with a PD-1 or PD-L1 inhibitor with or without platinum-based chemotherapy; recovered from all acute toxicities (≤ Grade 1) due to prior therapy; adequate renal and hepatic function; and no known history of significant cardiac, hepatic or ocular disease.

Dose Escalation Phase:

Following screening, a total of up to 36 subjects are anticipated to establish the dose limiting toxicity (DLT) and maximum tolerated doses (MTDs) of VIC-1911 monotherapy and VIC-1911 in combination with sotorasib therapy.

Cohort 1a: Subjects who are refractory to or relapsed on prior KRAS G12C inhibitor therapy will receive VIC-1911 monotherapy. Up to 24 subjects are anticipated in this cohort.

Cohort 1b: Subjects who are refractory to or relapsed on prior KRAS G12C inhibitor therapy or are naïve to KRASG12C inhibitor therapy will receive VIC-1911 plus sotorasib combination therapy. Up to 12 subjects are anticipated in this cohort.

A 3+3 dose escalation schema will be followed to establish the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of VIC-1911 and VIC-1911 plus sotorasib combination. A total of at least 6 subjects will be treated at the MTD in each group before initiating the Expansion Phase.

Expansion Phase:

Following screening, a total of 104 subjects with KRAS G12C-mutated locally advanced or metastatic NSCLC are anticipated to expand the disease treatment settings of VIC-1911 as monotherapy or in combination with sotorasib. VIC-1911 monotherapy and VIC-1911 plus sotorasib combination therapy will be administered orally at the MTDs established during the Dose Escalation Phase.

Cohort 2a: Subjects who are refractory to or relapsed on prior KRAS G12C inhibitor therapy will receive VIC-1911 monotherapy. (n=29)

Cohort 2b: Subjects who are refractory to or relapsed on prior KRAS G12C inhibitor therapy will receive VIC-1911 plus sotorasib combination therapy.(n=29)

Cohort 2c: Subjects who are naïve to KRAS G12C inhibitor therapy will receive VIC-1911 plus sotorasib combination therapy. (n=46)

VIC-1911 and sotorasib will be taken in the fasted state, 1 hour before or 2 hours after a meal.

Subjects who demonstrate clinical benefit (CR, PR or SD) will be allowed to continue therapy with VIC-1911 and sotorasib until progression of disease, observation of unacceptable adverse events, intercurrent illness or changes in the subject's condition that prevents further study participation.

Disease response will be assessed according to Response Evaluation Criteria in Solid Tumors (RECIST v.1.1).

Blood for hematology, coagulation parameters and serum chemistry determinations and urine will be collected, ECGs will be taken and ophthalmologic exams will be conducted during the study.

Blood will be taken for PK assessment of VIC-1911 and PD assessment of circulating tumor DNA biomarker determinations.

Tumor biopsies will be taken from consenting subjects at Screening and on-study for correlative biomarker determinations. Results will be correlated with clinical outcome.

Eligibility criteria: Inclusion Criteria:

1. Males and females ≥ 18 years of age
2. Have locally advanced or metastatic histologically or cytologically confirmed NSCLC, KRAS G12C-mutated
3. The presence of a KRAS G12C mutation should be established prior to entry as assessed in a CLIA qualified laboratory. Testing may be done on tumor tissue (archival or fresh) or on ctDNA from blood.
4. Have received at least 1 prior line of cancer therapy with a PD-1 or PD-L1 inhibitor with or without platinum-based chemotherapy (unless subject is not eligible or refuses chemotherapy or PD-1/PD-L1 therapy and have documented progression on all prior cancer therapies
5. Dose Escalation Phase:

   * Cohort 1a: (VIC-1911 monotherapy): Locally advanced or metastatic NSCLC refractory to or relapsed on at least 1 prior cancer therapy as noted above, and relapsed/refractory on KRAS G12C inhibitor therapy as the most recent cancer therapy prior to study
   * Cohort 1b: (VIC-1911 plus sotorasib): Locally advanced or metastatic NSCLC:

     * Refractory to or relapsed on at least 1 prior cancer therapy as noted above, and relapsed/refractory on KRAS G12C inhibitor therapy as the most recent cancer therapy prior to study, or
     * Refractory to or relapsed on at least 1 prior cancer therapy as noted above, and Naïve to KRAS G12C inhibitor therapy
6. Expansion Phase 1b:

   * Cohort 2a: (VIC-1911 monotherapy): Locally advanced or metastatic NSCLC refractory to or relapsed on at least 1 prior cancer therapy as noted above, and relapsed/refractory on KRAS G12C inhibitor therapy as the most recent cancer therapy prior to study
   * Cohort 2b: (VIC-1911 plus sotorasib): Locally advanced or metastatic NSCLC refractory to or relapsed on at least 1 prior cancer therapy as noted above, and relapsed/refractory on KRAS G12C inhibitor therapy as the most recent cancer therapy prior to study
   * Cohort 2c: (VIC-1911 plus sotorasib): Locally advanced or metastatic NSCLC refractory to or relapsed on at least 1 prior cancer therapy as noted above, and naïve to KRAS G12C inhibitor therapy
7. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
8. Have discontinued previous treatments for cancer, except for sotorasib for subjects to receive VIC-1911 plus sotorasib combination treatment, and have resolution, except where otherwise stated in the inclusion criteria, of all clinically significant toxic effects of prior cancer treatment, surgery, or radiotherapy to Grade ≤ 1
9. Adequate performance status: Eastern Cooperative Oncology Group (ECOG) ≤ 2
10. Life expectancy of ≥ 3 months
11. Subjects with brain metastases:

    11.1 KRAS G12C inhibitor naïve: Subjects with clinically stable (i.e., no increase in corticosteroid requirement) asymptomatic brain metastases are allowed without prior local therapy, as long as all lesions are each ≤ 1 cm. Prior local therapy is required (e.g., stereotactic radiosurgery \[SRS\], stereotactic body radiation therapy \[SBRT\], or surgery) for any lesion \> 1 cm or any lesion that is symptomatic. Subjects must be clinically stable and asymptomatic following local therapy.

    11.2 KRAS G12C inhibitor pretreated: Subjects with clinically stable (i.e., no increase in corticosteroid requirement) asymptomatic brain metastases following prior local therapy (e.g., SRS, SBRT or surgery) are allowed.
12. Adequate hematologic without ongoing transfusion support:

    * Hemoglobin (Hb) ≥ 8 g/dL
    * Absolute neutrophil count (ANC) ≥ 1.0 x 10\^9 cells/L
    * Platelets ≥ 75 x 10\^9 cells/L
13. Adequate renal and hepatic function:

    * Calculated creatinine clearance ≥ 50 mL/minute x 1.73 m2 per the Cockcroft-Gault formula
    * Total bilirubin ≤ 1.5 times the ULN, unless due to Gilbert's disease, or \< 3 times the ULN for subjects with liver metastases
    * ALT/AST ≤ 2 times the ULN, or \< 3 times the ULN for subjects with liver metastases
14. Negative serum pregnancy test within 14 days prior to the first dose of study therapy for women of child-bearing potential (WCBP). Sexually active WCBP and male subjects must agree to use adequate methods to avoid pregnancy throughout the study and for 28 days after the completion of study treatment.
15. Ability to proved written informed consent

Exclusion Criteria:

1. Serious cardiac condition within the last 6 months, such as uncontrolled arrhythmia, myocardial infarction, unstable angina or heart disease defined by the New York Heart Association (NYHA) Class III or Class IV
2. QT interval corrected for rate (QTc) \> 480 msec on the ECG obtained at Screening using Fridericia method for QTc calculation
3. Medications that are inhibitors or inducers of UDP-glucuronosyltransferases (UGTs) are prohibited in the Dose Escalation Phase
4. History of corneal epithelial cysts or other ocular events leading to blurred vision, or has medically relevant abnormalities identified on screening ophthalmologic examination
5. Symptomatic pneumonitis/interstitial lung disease requiring medical intervention
6. Symptomatic central nervous system metastasis
7. Leptomeningeal carcinomatosis
8. Inability to swallow oral medication
9. Gastrointestinal conditions that could impair absorption or tolerance of study drugs
10. Current hematologic malignancies
11. Second, active primary solid tumor malignancy that, in the judgement of the Investigator or Sponsor Medical Monitor, may affect the interpretation of results, with the exception of carcinoma in situ of any origin, non-muscle invasive bladder cancer, and Gleason \< 3+3 prostate cancer
12. Active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) requiring treatment within the last week prior to study treatment
13. Other active infection requiring IV antibiotic usage within the last week prior to study treatment
14. Unable to tolerate marketed dose of KRAS G12C inhibitor on prior therapy for subjects to be enrolled in combination VIC-1911 plus sotorasib treatment cohorts. Alternatively, these subjects may be able to enroll in the VIC-1911 monotherapy treatment cohort, upon discussion with the Medical Monitor and Study Chair.
15. Previous MEK or EGFR inhibitor therapy
16. Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results
17. Receipt of an investigational product on a clinical trial within 5 elimination half-lives or within 28 days, whichever is shorter, prior to C1D1 on this study, or currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
18. Previously completed or withdrawn from any other study investigating an aurora kinase A inhibitor
19. Known hypersensitivity to VIC-1911 or its components
20. If female, pregnant, breast-feeding, or planning to become pregnant

Primary outcomes:
measure: Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)
timeFrame: 9 months
Secondary outcomes:
measure: Objective Response Rate
timeFrame: Assessed at the end of Cycle 2 and every 2 cycles thereafter up to 8 months. Each cycle is 28 days.
measure: Duration of Response
timeFrame: Assessed at the end of Cycle 2 and every 2 cycles thereafter up to 8 months. Each cycle is 28 days.
measure: Time to Response
timeFrame: Assessed at the end of Cycle 2 and every 2 cycles thereafter up to 8 months. Each cycle is 28 days.
measure: Disease Control Rate
timeFrame: Assessed at the end of Cycle 2 and every 2 cycles thereafter up to 8 months. Each cycle is 28 days.
measure: Progression-Free Survival
timeFrame: Assessed from the date of the first dose of study drug to the first evidence of disease progression or death, whichever is earlier, assessed up to 9 months
measure: Overall Survival
timeFrame: Assessed from the date of the first dose of study drug to date of death from any cause, assessed up to 9 months
Other outcomes:
measure: Mean Plasma Concentrations of VIC-1911 Alone and in Combination With Sotorasib
timeFrame: Was to be assessed C1D1; C1D15; C2D1; C4D1; C6D1 (each cycle is 28 days). The study terminated early with only 3 subjects analyzed C1D1 and 2 subjects analyzed C1D15.
measure: Circulating Tumor DNA (ctDNA) in Plasma (Pharmacodynamic Endpoint)
timeFrame: Cycle 1 Day 1 pre-dose and at progression of disease
measure: Tumor Biopsies for Biomarker Assessment (Pharmacodynamic Endpoint)
timeFrame: Pre-study, Cycle 3 Day 1, and at progression of disease
measure: Effect of de Novo Versus Acquired Resistance to KRASG12C Inhibitor Therapy, in Subjects Refractory to or Relapsed on Prior KRAS G12C Inhibitor Therapy
timeFrame: 42 months
Locations:
city: Sacramento
country: United States
facility: University of California Davis
state: California
city: North Haven
country: United States
facility: Yale Cancer Center
state: Connecticut
city: Atlanta
country: United States
facility: Emory University Winship Cancer Center
state: Georgia
city: Baltimore
country: United States
facility: University of Maryland Cancer Center
state: Maryland
city: New York
country: United States
facility: New York University Langone Health Perlmutter Cancer Cancer
state: New York
Study officials:
affiliation: Yale Cancer Center, Yale University
name: Sarah Goldberg, MD, MPH
role: STUDY_CHAIR
affiliation: Vitrac Therapeutics, LLC
name: Linda J Paradiso, DVM
role: STUDY_DIRECTOR
References: